Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Cancer Discov. 2020 Nov 24;11(2):308–325. doi: 10.1158/2159-8290.CD-20-1408

Figure 3.

Figure 3

A: The first-line progression free survival (PFS1) in the ITT group (red) versus the non-ITT group (blue). Figure 3B: Rainbow waterfall plot demonstrating objective response rate (ORR1, 74%) and disease control rate (DCR1, 99%) by molecular group to first-line cytotoxic therapy plus matched monoclonal antibody among patient within the ITT population having baseline measurable disease (N=54/68). Inset, waterfall plot for ORR1 ITT treated per protocol.